Gubra

Gubra operates a hybrid model, generating revenue through its preclinical CRO services while investing in an internal pipeline of novel therapeutics for metabolic disorders. This strategy leverages its deep expertise in in vivo pharmacology, peptide chemistry, and histology to de-risk its own R&D and fund discovery. The company is privately funded and based in Denmark, positioning it at the intersection of service provision and innovative drug development in a high-growth therapeutic area.

Integrated preclinical platform combining advanced in vivo pharmacology (specialized rodent models), molecular histology, and peptide chemistry/engineering for target validation and drug discovery in metabolic diseases.

In drug discovery, Gubra competes with numerous biotechs and pharma giants (e.g., Novo Nordisk, Eli Lilly) developing next-generation obesity/diabetes therapies. As a CRO, it competes with large global players (Charles River, Labcorp) and niche metabolic specialists, differentiating through deep, integrated expertise in peptide-centric metabolic disease models.